A multicenter, open-label, phase II study of PGG beta-glucan and pembrolizumab in patients (pts) with advanced melanoma (MEL) following progression on treatment with checkpoint inhibitors (CPI) or triple negative breast cancer (TNBC) failing front-line chemotherapy for metastatic disease
Iglesias, Jose Luis, Prathikanti, Radha, Ma, Bo, Mattson, Paulette, Kedrowski, Deb, Lowe, Jamie, Bose, Nandita, Ertelt, Katie E., Ottoson, Nadine, Uhlik, Mark T., Graff, Jeremy, Huhn, Richard Dale, Chisamore, Michael Jon
Published in Journal of clinical oncology (20.05.2017)
Published in Journal of clinical oncology (20.05.2017)
Get full text
Journal Article